Novartis delayed reveal of bad data for $2.1 million gene therapy. Now patients and pharma suffer.


20 August 2019 - Novartis CEO had a rocky start to his tenure. 

Last year, the newly appointed boss was in a car when he learned that his predecessor had signed a $1.2 million contract with then Trump attorney and fixer, Michael Cohen, for him to provide access to the Trump administration. As he told STAT’s Matt Herper: “I was not mentally prepared, nor prepared from a crisis-management standpoint. It’s not a phone call you expect to get from your mother, which was one of the first people I heard from.” 

One would assume that this was a learning moment for the young Novartis CEO.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Regulation , Gene therapy , Data